slides · global inventory
List
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,471
Current window 88,891-88,920
Pages 3,683
Rows per page 30
Component
88,891-88,920 of 110,471
13
The slide uses a 5-step process flow diagram to explain the technical methodology.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
14
The slide highlights the efficacy of the de novo design model by showing a histogram of binding affinities and key performance metrics.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
17
The slide highlights the 'zero-shot' nature of the model, emphasizing the lack of lead optimization and the successful application across four distinct therapeutic targets.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
21
Uses a Venn diagram to represent the intersection of three properties optimized by AI.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
22
The slide uses a visual comparison between a small sampled space (50k) and a massive hypothetical space (7x10^6) to illustrate the efficiency of the AI approach.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
24
The slide uses a process flow diagram to show AI input leading to an antibody structure, which then branches into three key benefits.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
26
The slide uses a histogram to visualize the distribution of binding affinity (-log10(KD)) for designed variants compared to the wild-type Trastuzumab baseline.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
30
Includes a biological diagram of TLS and a Kaplan-Meier survival curve.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
32
The slide highlights the scale of the antibody discovery pipeline and the distribution of therapeutic focus areas.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
40
Uses a four-column layout to categorize value propositions.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
41
PoS stands for Probability of Success. The slide uses a timeline framework to contrast traditional drug development with Absci's approach.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
03
The slide details a corporate M&A event and associated private placement financing.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Setup1 hit
04
The slide provides a breakdown of shares and conversion ratios related to a merger and concurrent financing.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Setup1 hit
05
The slide uses a pipeline table format to show the progression of various drug candidates (SPY001-SPY230) across discovery, IND-enabling, and clinical stages.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Golden Circle1 hit
09
Aeglea BioTherapeutics | Investor Presentation Deck | 56 slidesAeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Golden Circle1 hit
16
The chart uses a dual-axis approach to imply a safety-efficacy trade-off, positioning vedolizumab as the 'safest' and highly effective.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
19
Includes structural biology visualization and dose-response curves for two different adhesion targets.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
20
The slide demonstrates bio-equivalence in binding affinity to a specific T-cell population.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
21
The chart compares SPY001 against two vedolizumab datasets (internal and Takeda).Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
22
Uses YTE modification as a mechanism for half-life extension.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
24
The chart compares benchmark induction remission rates with vedolizumab exposure quartiles.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
25
Data from GEMINI 1 study; highlights that higher drug concentration does not necessarily correlate with higher efficacy in maintenance.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
31
The chart uses a horizontal bar format to compare clinical remission percentages across different drug targets (TL1A, a4b7, IL-23s, TNFa, S1P1s, JAKs).Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
34
Includes visual representation of antibody binding mechanisms.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
35
The slide uses two charts: a dose-response curve (left) and a scatter plot (right) to demonstrate competitive advantage.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
36
Aeglea BioTherapeutics | Investor Presentation Deck | 56 slidesAeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
52
The slide serves as a credibility transfer by showcasing the partner's team and achievements.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
55
The diagram illustrates the mechanism of FcRn-mediated antibody recycling, contrasting physiological affinity with high affinity.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
07
Includes a disclaimer regarding the separation of the oncology business and a footnote about non-GAAP reconciliation.Alkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Key Performance Indicator OverviewLoop · Cost Of Inaction1 hit
10
The chart displays both weekly data and a 4-week rolling average.Alkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Key Performance Indicator OverviewLoop · Cost Of Inaction1 hit